The Chronic Kidney Disease Drugs Market is expected to register a CAGR of 5% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The Chronic Kidney Disease Drugs Market report covers segmental analysis by Drug Class (ACE Inhibitors, Angiotensin-II receptor blockers, Beta-blockers, Calcium channel blockers, Diuretics, Erythropoiesis-stimulating agents (ESAs), Others); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others); End User (Hospitals, Specialty Clinics, Others), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken down at the regional level and major countries. The report Offers the Value in US$ for the above analysis and segments.
Purpose of the ReportThe report Chronic Kidney Disease Drugs Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Chronic Kidney Disease Drugs Market Segmentation
Drug Class- ACE Inhibitors
- Angiotensin-II receptor blockers
- Beta-blockers
- Calcium channel blockers
- Diuretics
- Erythropoiesis-stimulating agents
- Hospital Pharmacies
- Retail Pharmacies
- Hospitals
- Specialty Clinics
Strategic Insights
Chronic Kidney Disease Drugs Market Growth Drivers- Rise in Investment and Research Funding for Kidney Disease: The propelling drivers for the CKD Drugs Market are investments in medical research and development, in particular concerning studies on kidney diseases. Public and private organizations realize that fighting kidney diseases is what everyone needs; therefore, this market will boom with innovative drug development and clinical trials. It can lead to acceptance of new drugs and allow a greater number of treatment options for Chronic Kidney Disease.
- Improved Patient Compliance and Monitoring Technologies: Advancement in patient monitoring and adherence management is a major trend that propels the Chronic Kidney Disease Drugs Market. It aids better monitoring of patients' health with the help of digital health tools, such as mobile applications and wearable devices. It comes with more individualized treatment plans and higher adherence toward prescribed therapies, thereby increasing the effectiveness of drugs for CKD and driving the market to grow.
- Growing Demand for Dialysis Drugs: Dialysis drugs are required as the patients of advanced-stage Chronic Kidney Disease face more demands for dialysis. This boosts up the demand for such drugs. The diseases like erythropoiesis-stimulating agents and phosphate binders in dialysis drugs help control symptoms and improve quality of life of patients having CKD. It is growing at a rapid pace due to an elevated prevalence of end-stage renal disease.
- Gene Therapy and Regenerative Medicine for CKD: That is expected to continue with the advancement of gene therapy and regenerative medicine studies. More possibilities about such treatments in the future will open up. Future treatments that might actually target the source of Chronic Kidney Disease might include stem cell-based therapies that repair damaged kidneys or regenerate renal tissues through gene editing techniques or tissue engineering. These new treatments will eventually pave the hope for patients suffering from advanced CKD, and in the end, the process of dialysis and kidney transplants might be a thing of the past, thus opening up new horizons in the CKD Drugs Market.
- Expansion of Non-Dialysis Therapeutic Options: The market for Chronic Kidney Disease Drugs will evolve further, and drugs that can manage CKD without dialysis may serve as the focus. Currently, treatments are more or less symptomatic or aimed at delaying the progression of disease. Future innovations would be targeted towards preserving longer kidney function or even partially restoring it. Drugs regulating pathways of kidney fibrosis, inflammation, or fibrosis-related pathways would still be excellent alternatives to dialysis and significantly reduce the associated cost of healthcare, ensuring even greater expansion in the market.
- Integration of Digital Health and Remote Monitoring: Digital health technologies and the monitoring of a patient from anywhere would be incorporated, as that will include telemedicine platforms along with wearables and mobile applications of health tracking, enabling patient's continuous or real-time surveillance of those experiencing CKD by delivering necessary information to healthcare specialists so that further changes can be done in plans. These technologies will boost compliance from patients, monitor the medication adherence and will alert about possible complications early, thus delivering improved outcomes that require increased demands of drugs capable of supporting such connected care. An enormous potential opportunity for the growth of market will be due to early diagnosis and preventive treatments for Chronic Kidney Disease.
- Shift Toward Preventive Treatments and Early Diagnosis: Recently, great importance has been given to early intervention with regard to advanced diagnostic tools and the sharp awareness of CKD risk factors. Demand for drugs designed to prevent further progression of renal damage in early-stage CKD patients would provide a market for preventive medicines. Pharmaceutical corporations might take advantage of the trend by promoting the drugs that prevent this disease from coming to its full stage. With a rapidly aging world, there lies a great chance of addressing the need for an increasingly growing requirement of CKD treatment drugs appropriate for geriatric patients. Old people are at an increased risk for developing CKD, and an increase in elderly population increases the demand for age-appropriate CKD drugs. Such drugs with fewer side effects and ease in administration to elderly patients will definitely have an impact on the market as well as on patient compliance and outcome.
- Increased Demand for Kidney Disease Treatment in Geriatric Populations: The global aging population presents an opportunity to address the growing need for CKD treatments tailored to geriatric patients. Older adults are at a higher risk for developing CKD, and as the number of elderly individuals rises, the demand for age-appropriate CKD drugs will increase. Companies developing drugs with fewer side effects and easier administration for the elderly could significantly impact the market, while also improving patient compliance and overall outcomes in this vulnerable population.
- Collaborations and Partnerships in CKD Drug Development: Collaborations and partnerships between pharmaceutical companies, academic institutions, and healthcare organizations represent another key opportunity in the Chronic Kidney Disease Drugs Market. By pooling resources, expertise, and data, these collaborations can accelerate the development of innovative treatments and expand clinical trials to a broader range of patient populations. Strategic partnerships could also lead to licensing agreements, distribution deals, and joint ventures, increasing market penetration and allowing companies to offer a wider range of CKD drugs to diverse global markets.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Chronic Kidney Disease Drugs Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Chronic Kidney Disease Drugs Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Chronic Kidney Disease Drugs Market is expected to register a CAGR of 5% from 2025-2031.
The major factors impacting the Chronic Kidney Disease Drugs Market are: Rise in Investment and Research Funding for Kidney Disease, Improved Patient Compliance and Monitoring Technologies and Growing Demand for Dialysis Drugs
Key future trends in this market are - Gene Therapy and Regenerative Medicine for CKD, Expansion of Non-Dialysis Therapeutic Options and Integration of Digital Health and Remote Monitoring
Key companies of this market are: AstraZeneca, Pfizer, Inc., Amgen Inc., Fibrogen, Inc., GlaxoSmithKline plc., F. Hoffmann -La Roche, AbbVie Inc., Akebia Therapeutics, Inc., Teva Pharmaceutical Industries, Ltd., Johnson and Johnson Services, Inc.
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Chronic Kidney Disease Drugs Market - By Drug Class
1.3.2 Chronic Kidney Disease Drugs Market - By Distribution Channel
1.3.3 Chronic Kidney Disease Drugs Market - By End User
1.3.4 Chronic Kidney Disease Drugs Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. CHRONIC KIDNEY DISEASE DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. CHRONIC KIDNEY DISEASE DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. CHRONIC KIDNEY DISEASE DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. CHRONIC KIDNEY DISEASE DRUGS - GLOBAL MARKET OVERVIEW
6.2. CHRONIC KIDNEY DISEASE DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. CHRONIC KIDNEY DISEASE DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. ACE INHIBITORS
7.3.1. Overview
7.3.2. ACE Inhibitors Market Forecast and Analysis
7.4. ANGIOTENSIN-II RECEPTOR BLOCKERS
7.4.1. Overview
7.4.2. Angiotensin-II receptor blockers Market Forecast and Analysis
7.5. BETA-BLOCKERS
7.5.1. Overview
7.5.2. Beta-blockers Market Forecast and Analysis
7.6. CALCIUM CHANNEL BLOCKERS
7.6.1. Overview
7.6.2. Calcium channel blockers Market Forecast and Analysis
7.7. DIURETICS
7.7.1. Overview
7.7.2. Diuretics Market Forecast and Analysis
7.8. ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)
7.8.1. Overview
7.8.2. Erythropoiesis-stimulating agents (ESAs) Market Forecast and Analysis
7.9. OTHERS
7.9.1. Overview
7.9.2. Others Market Forecast and Analysis
8. CHRONIC KIDNEY DISEASE DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL PHARMACIES
8.3.1. Overview
8.3.2. Hospital Pharmacies Market Forecast and Analysis
8.4. RETAIL PHARMACIES
8.4.1. Overview
8.4.2. Retail Pharmacies Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. CHRONIC KIDNEY DISEASE DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. SPECIALTY CLINICS
9.4.1. Overview
9.4.2. Specialty Clinics Market Forecast and Analysis
9.5. OTHERS
9.5.1. Overview
9.5.2. Others Market Forecast and Analysis
10. CHRONIC KIDNEY DISEASE DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Chronic Kidney Disease Drugs Market Overview
10.1.2 North America Chronic Kidney Disease Drugs Market Forecasts and Analysis
10.1.3 North America Chronic Kidney Disease Drugs Market Forecasts and Analysis - By Drug Class
10.1.4 North America Chronic Kidney Disease Drugs Market Forecasts and Analysis - By Distribution Channel
10.1.5 North America Chronic Kidney Disease Drugs Market Forecasts and Analysis - By End User
10.1.6 North America Chronic Kidney Disease Drugs Market Forecasts and Analysis - By Countries
10.1.6.1 United States Chronic Kidney Disease Drugs Market
10.1.6.1.1 United States Chronic Kidney Disease Drugs Market by Drug Class
10.1.6.1.2 United States Chronic Kidney Disease Drugs Market by Distribution Channel
10.1.6.1.3 United States Chronic Kidney Disease Drugs Market by End User
10.1.6.2 Canada Chronic Kidney Disease Drugs Market
10.1.6.2.1 Canada Chronic Kidney Disease Drugs Market by Drug Class
10.1.6.2.2 Canada Chronic Kidney Disease Drugs Market by Distribution Channel
10.1.6.2.3 Canada Chronic Kidney Disease Drugs Market by End User
10.1.6.3 Mexico Chronic Kidney Disease Drugs Market
10.1.6.3.1 Mexico Chronic Kidney Disease Drugs Market by Drug Class
10.1.6.3.2 Mexico Chronic Kidney Disease Drugs Market by Distribution Channel
10.1.6.3.3 Mexico Chronic Kidney Disease Drugs Market by End User
10.2. EUROPE
10.2.1 Europe Chronic Kidney Disease Drugs Market Overview
10.2.2 Europe Chronic Kidney Disease Drugs Market Forecasts and Analysis
10.2.3 Europe Chronic Kidney Disease Drugs Market Forecasts and Analysis - By Drug Class
10.2.4 Europe Chronic Kidney Disease Drugs Market Forecasts and Analysis - By Distribution Channel
10.2.5 Europe Chronic Kidney Disease Drugs Market Forecasts and Analysis - By End User
10.2.6 Europe Chronic Kidney Disease Drugs Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Chronic Kidney Disease Drugs Market
10.2.6.1.1 Germany Chronic Kidney Disease Drugs Market by Drug Class
10.2.6.1.2 Germany Chronic Kidney Disease Drugs Market by Distribution Channel
10.2.6.1.3 Germany Chronic Kidney Disease Drugs Market by End User
10.2.6.2 France Chronic Kidney Disease Drugs Market
10.2.6.2.1 France Chronic Kidney Disease Drugs Market by Drug Class
10.2.6.2.2 France Chronic Kidney Disease Drugs Market by Distribution Channel
10.2.6.2.3 France Chronic Kidney Disease Drugs Market by End User
10.2.6.3 Italy Chronic Kidney Disease Drugs Market
10.2.6.3.1 Italy Chronic Kidney Disease Drugs Market by Drug Class
10.2.6.3.2 Italy Chronic Kidney Disease Drugs Market by Distribution Channel
10.2.6.3.3 Italy Chronic Kidney Disease Drugs Market by End User
10.2.6.4 Spain Chronic Kidney Disease Drugs Market
10.2.6.4.1 Spain Chronic Kidney Disease Drugs Market by Drug Class
10.2.6.4.2 Spain Chronic Kidney Disease Drugs Market by Distribution Channel
10.2.6.4.3 Spain Chronic Kidney Disease Drugs Market by End User
10.2.6.5 United Kingdom Chronic Kidney Disease Drugs Market
10.2.6.5.1 United Kingdom Chronic Kidney Disease Drugs Market by Drug Class
10.2.6.5.2 United Kingdom Chronic Kidney Disease Drugs Market by Distribution Channel
10.2.6.5.3 United Kingdom Chronic Kidney Disease Drugs Market by End User
10.2.6.6 Rest of Europe Chronic Kidney Disease Drugs Market
10.2.6.6.1 Rest of Europe Chronic Kidney Disease Drugs Market by Drug Class
10.2.6.6.2 Rest of Europe Chronic Kidney Disease Drugs Market by Distribution Channel
10.2.6.6.3 Rest of Europe Chronic Kidney Disease Drugs Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Chronic Kidney Disease Drugs Market Overview
10.3.2 Asia-Pacific Chronic Kidney Disease Drugs Market Forecasts and Analysis
10.3.3 Asia-Pacific Chronic Kidney Disease Drugs Market Forecasts and Analysis - By Drug Class
10.3.4 Asia-Pacific Chronic Kidney Disease Drugs Market Forecasts and Analysis - By Distribution Channel
10.3.5 Asia-Pacific Chronic Kidney Disease Drugs Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Chronic Kidney Disease Drugs Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Chronic Kidney Disease Drugs Market
10.3.6.1.1 Australia Chronic Kidney Disease Drugs Market by Drug Class
10.3.6.1.2 Australia Chronic Kidney Disease Drugs Market by Distribution Channel
10.3.6.1.3 Australia Chronic Kidney Disease Drugs Market by End User
10.3.6.2 China Chronic Kidney Disease Drugs Market
10.3.6.2.1 China Chronic Kidney Disease Drugs Market by Drug Class
10.3.6.2.2 China Chronic Kidney Disease Drugs Market by Distribution Channel
10.3.6.2.3 China Chronic Kidney Disease Drugs Market by End User
10.3.6.3 India Chronic Kidney Disease Drugs Market
10.3.6.3.1 India Chronic Kidney Disease Drugs Market by Drug Class
10.3.6.3.2 India Chronic Kidney Disease Drugs Market by Distribution Channel
10.3.6.3.3 India Chronic Kidney Disease Drugs Market by End User
10.3.6.4 Japan Chronic Kidney Disease Drugs Market
10.3.6.4.1 Japan Chronic Kidney Disease Drugs Market by Drug Class
10.3.6.4.2 Japan Chronic Kidney Disease Drugs Market by Distribution Channel
10.3.6.4.3 Japan Chronic Kidney Disease Drugs Market by End User
10.3.6.5 South Korea Chronic Kidney Disease Drugs Market
10.3.6.5.1 South Korea Chronic Kidney Disease Drugs Market by Drug Class
10.3.6.5.2 South Korea Chronic Kidney Disease Drugs Market by Distribution Channel
10.3.6.5.3 South Korea Chronic Kidney Disease Drugs Market by End User
10.3.6.6 Rest of Asia-Pacific Chronic Kidney Disease Drugs Market
10.3.6.6.1 Rest of Asia-Pacific Chronic Kidney Disease Drugs Market by Drug Class
10.3.6.6.2 Rest of Asia-Pacific Chronic Kidney Disease Drugs Market by Distribution Channel
10.3.6.6.3 Rest of Asia-Pacific Chronic Kidney Disease Drugs Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Chronic Kidney Disease Drugs Market Overview
10.4.2 Middle East and Africa Chronic Kidney Disease Drugs Market Forecasts and Analysis
10.4.3 Middle East and Africa Chronic Kidney Disease Drugs Market Forecasts and Analysis - By Drug Class
10.4.4 Middle East and Africa Chronic Kidney Disease Drugs Market Forecasts and Analysis - By Distribution Channel
10.4.5 Middle East and Africa Chronic Kidney Disease Drugs Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Chronic Kidney Disease Drugs Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Chronic Kidney Disease Drugs Market
10.4.6.1.1 South Africa Chronic Kidney Disease Drugs Market by Drug Class
10.4.6.1.2 South Africa Chronic Kidney Disease Drugs Market by Distribution Channel
10.4.6.1.3 South Africa Chronic Kidney Disease Drugs Market by End User
10.4.6.2 Saudi Arabia Chronic Kidney Disease Drugs Market
10.4.6.2.1 Saudi Arabia Chronic Kidney Disease Drugs Market by Drug Class
10.4.6.2.2 Saudi Arabia Chronic Kidney Disease Drugs Market by Distribution Channel
10.4.6.2.3 Saudi Arabia Chronic Kidney Disease Drugs Market by End User
10.4.6.3 U.A.E Chronic Kidney Disease Drugs Market
10.4.6.3.1 U.A.E Chronic Kidney Disease Drugs Market by Drug Class
10.4.6.3.2 U.A.E Chronic Kidney Disease Drugs Market by Distribution Channel
10.4.6.3.3 U.A.E Chronic Kidney Disease Drugs Market by End User
10.4.6.4 Rest of Middle East and Africa Chronic Kidney Disease Drugs Market
10.4.6.4.1 Rest of Middle East and Africa Chronic Kidney Disease Drugs Market by Drug Class
10.4.6.4.2 Rest of Middle East and Africa Chronic Kidney Disease Drugs Market by Distribution Channel
10.4.6.4.3 Rest of Middle East and Africa Chronic Kidney Disease Drugs Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Chronic Kidney Disease Drugs Market Overview
10.5.2 South and Central America Chronic Kidney Disease Drugs Market Forecasts and Analysis
10.5.3 South and Central America Chronic Kidney Disease Drugs Market Forecasts and Analysis - By Drug Class
10.5.4 South and Central America Chronic Kidney Disease Drugs Market Forecasts and Analysis - By Distribution Channel
10.5.5 South and Central America Chronic Kidney Disease Drugs Market Forecasts and Analysis - By End User
10.5.6 South and Central America Chronic Kidney Disease Drugs Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Chronic Kidney Disease Drugs Market
10.5.6.1.1 Brazil Chronic Kidney Disease Drugs Market by Drug Class
10.5.6.1.2 Brazil Chronic Kidney Disease Drugs Market by Distribution Channel
10.5.6.1.3 Brazil Chronic Kidney Disease Drugs Market by End User
10.5.6.2 Argentina Chronic Kidney Disease Drugs Market
10.5.6.2.1 Argentina Chronic Kidney Disease Drugs Market by Drug Class
10.5.6.2.2 Argentina Chronic Kidney Disease Drugs Market by Distribution Channel
10.5.6.2.3 Argentina Chronic Kidney Disease Drugs Market by End User
10.5.6.3 Rest of South and Central America Chronic Kidney Disease Drugs Market
10.5.6.3.1 Rest of South and Central America Chronic Kidney Disease Drugs Market by Drug Class
10.5.6.3.2 Rest of South and Central America Chronic Kidney Disease Drugs Market by Distribution Channel
10.5.6.3.3 Rest of South and Central America Chronic Kidney Disease Drugs Market by End User
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. CHRONIC KIDNEY DISEASE DRUGS MARKET, KEY COMPANY PROFILES
12.1. ASTRAZENECA
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. PFIZER INC
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. AMGEN INC
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. FIBROGEN, INC
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. GLAXOSMITHKLINE PLC
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. F. HOFFMANN-LA ROCHE
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. ABBVIE INC.
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. AKEBIA THERAPEUTICS, INC
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. TEVA PHARMACEUTICAL INDUSTRIES LTD
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. JOHNSON AND JOHNSON SERVICES, INC.
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. AstraZeneca
2. Pfizer Inc
3. Amgen Inc
4. FibroGen, Inc
5. GlaxoSmithKline plc
6. F. Hoffmann-La Roche
7. AbbVie Inc.
8. Akebia Therapeutics, Inc
9. Teva Pharmaceutical Industries Ltd
10. Johnson and Johnson Services, Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For